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OBJECTIVES: To compare medication adherence and direct medical costs between
duloxetine and pregabalin among fibromyalgia patients. METHODS: A retrospec-
tive cohort study design was used along with a large US national commercial
claims database (20062009). Fibromyalgia patients who initiated duloxetine or
pregabalin in 2008 at age between 18 and 64, andwith continuous health insurance
1 year before and 1 year after initiation were assigned to a duloxetine initiator
cohort or a pregabalin initiator cohort based on their initiated agent. Medication
adherence of duloxetine or pregabalin, measured by total supply days, medication
possession ratio (MPR) and proportion of patients with MPR0.8, and direct medi-
cal costs, measured by annual costs per patient, were assessed and compared
between the cohorts in the year following the initiation. Bootstrapping and pro-
pensity score stratification methods were used to adjust for distribution bias, as
well as cross-cohort differences in demographics, clinical and economic charac-
teristics, and medication history prior to the initiation. RESULTS: Both the dulox-
etine (n 3,033) and pregabalin (n4,838) cohorts had amean initiation age around
49 years, 89% were female. In the post-initiation year, compared to the pregabalin
cohort, the duloxetine cohort had higher totally annual supply days (273.5 vs. 176.6,
p0.05), higherMPR (0.7 vs. 0.5, p0.05) andmore patients withMPR0.8 (45.1% vs.
29.4%, p0.05). Further, relative to pregabalin initiators, duloxetine initiators had
lower inpatient costs ($2,994.9 vs. $4,949.6, p0.05), low outpatient costs ($8,259.6
vs. $10,312.2, p0.05), similar medication costs ($5,214.6 vs. $5,290.8, p0.05), and
lower total costs ($16,469.1 vs. $20,552.6, p0.05) in the post-initiation year.
CONCLUSIONS: In a real-world setting, fibromyalgia patients who initiated dulox-
etine in 2008 were associated with higher adherence and lower inpatient, outpa-
tient and total medical costs than those who initiated pregabalin.
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OBJECTIVES: To evaluate real-world outcomes among elderly patients (65 years)
with type 2 diabetes mellitus (T2DM) initiating insulin treatment with insulin
glargine via disposable pen (IG-Pen) or conventional vial/syringe (IG-Vial).
METHODS: The MarketScan® Medicare database was used to identify T2DM pa-
tients 65 years who initiated insulin treatment with IG-Pen or IG-Vial from Janu-
ary 2007 through June 2009. All patients had continuous health plan coverage for
6months before (baseline) and1 year after the index date (follow-up), andwere
insulin-naïve but had 1 oral anti-diabetes drug (OAD) or glucagon-like peptide-1
(GLP-1) analog during the baseline period. Endpoints included 1-year treatment
persistence (continuous study drug use without discontinuation) and adherence
(adjusted medication possession ratio: aMPR), hypoglycemia-related events,
healthcare utilization and costs. Stringent 1:1 propensity score matching was ap-
plied to remove observed baseline selection bias between the two cohorts.
RESULTS: A total of 5,860 patients were matched and analyzed (n2,930 in each
cohort; 44% women; median baseline age 74 years, number of OADs 2.1, Charlson
comorbidity index 1.29). During the 1-year follow-up, those who initiated with
IG-Pen were more persistent (58.2% vs. 50.8%; P0.0001), and adherent (aMPR 0.69
vs. 0.64; P0.0001), had lower daily average consumption of insulin (28.6 U/day vs.
32.0 U/day; P0.0002), were less likely to have hospitalization (all-cause 33.0% vs.
37.5%, P0.0002; diabetes-related 16.7% vs. 18.8%, P0.037), and had similar total
healthcare costs ($22,265 vs. $21,669; P0.5085), despite higher diabetes drug costs
($2,166 vs. $1,907; P0.0001). Hypoglycemia-related event rates were 8.6% with
IG-Pen vs. 10.4% with IG-Vial (P0.0164). CONCLUSIONS: This real-world study
showed that for elderly T2DM patients initiating insulin treatment, using a pen
rather than vial/syringe was associated with better treatment persistence and
compliance, without increasing healthcare costs during the first year after initia-
tion. These results may assist with clinical decision making and help optimize
T2DM management in elderly patients.
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OBJECTIVES:Advancements in the econometricmodeling of discrete choice exper-
iment (DCE) data allow for the quantification of individual-specific utility. With a
view to improve the precision and face validity of DCE-derived willingness to pay
(WTP) estimates, we investigate incorporating a ‘choice certainty’ question into the
elicitation and estimation of DCE data.METHODS: The DCE elicited parents’ pref-
erences surrounding drug treatment for juvenile idiopathic arthritis. Two alterna-
tives in each question differed on six attributes: drug administration, child re-
ported pain, participation in activities, side-effects, school days missed, and cost.
Respondents rated the certainty for each of their choices on a Likert scale. The
mixed logit model allowed estimating individual-specific utility values. Respon-
dents’ choice certainty was incorporated into the model by re-weighting the sim-
ulated likelihood function. The D-error metric was used to investigate improve-
ments in precision. Monte Carlo simulation techniques were used to generate
individual-level population WTP estimates to investigate face validity. RESULTS:
105 parents of children with juvenile idiopathic arthritis at The Hospital for Sick
Children, Toronto, Canada completed 16 choice and choice-certainty questions.
The D-error statistic demonstrated a 53% gain in efficiency under the choice cer-
tainty approach. Under the standard approach, the mean WTP for a child who
moved from responding inadequately to methotrexate and adequately to etaner-
cept was $2,105 per month; 95% of the simulated individual-level population WTP
estimates fell between $360 and $12,743 per month. When choice certainty was
accounted for, mean willingness to pay was $2,167 and 95% of the simulated indi-
vidual-level population estimates were between $405 and $11,866. CONCLUSIONS:
The stated preferences of parents’ of children with juvenile idiopathic arthritis
suggest that this population is, on average, willing to pay $2,167 per month to
improve children’s well being. The choice certainty approach improved the preci-
sion of the parameter estimates and the range of willingness to pay values.
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OBJECTIVES: Primary stroke centers (PSC) have been shown to improve survival in
patients with acute ischemic stroke (AIS). The objective of this study was to eval-
uate the cost-effectiveness of treating AIS patients in a PSC compared with a non-
PSC hospital setting.METHODS: A decision analytic model was developed to proj-
ect the lifetime outcomes and costs for AIS patients. Clinical data were derived
from a recent observational study comparing existing PSC- and non-PSC-admitted
patients, the NINDS and ECASS III clinical trials, longitudinal cohort studies, and
health state preference studies. Annual cost data were based on Medicare reim-
bursement and other published sources, and did not include start-up costs. The
model used a health care payer perspective, and the primary outcomes were in-
cremental life expectancy, quality-adjusted life years (QALYs), and health care
costs. Sensitivity and scenario analyses were performed to evaluate uncertainty in
the results. RESULTS: Admission to an existing PSC resulted in a gain of 0.22 years
of life (95% credible range [CR], 0.12 - 0.33) and 0.15 QALYs (95% CR, 0.08 - 0.23) per
patient, at a cost of $3600 (95% CR, $2400 - $5000) per patient, compared with
admission to a non-PSC hospital. The incremental cost per QALY gained was
$24,000, and the results in all probabilistic simulations were below the $100,000/
QALY threshold. The cost-effectiveness improved as the number of stroke patients
admitted per year and use of recombinant tissue plasminogen activator increased.
CONCLUSIONS: Modeling analyses support the hypotheses that PSCs provide
meaningful long-term benefits to AIS patients and are cost-effective.
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OBJECTIVES: Absolute risk assessment (ARA) is promoted for guiding osteoporosis
treatment decisions. Competing guidelines lack clarity on how to incorporate ARA
into practice. We compared 6 strategies to identify one that minimized cost and
optimized quality-adjusted life years (QALYs) in United States (US) veterans.
METHODS:We developed a Markov model comparing 6 strategies in elderly male
veterans including (1) ARA alone, (2) ARA in concert with BMD screening, (3) BMD
screening alone, (4) waiting for fracture, (5) doing nothing, and (6) an approxima-
tion of current care, which included a combination of strategies 2-5. Health states
included community, nursing-home, and death. Three models with different as-
sumptions concerning treatment efficacy among high-risk versus osteoporotic pa-
tients were developed: equivalent, reduced, and lacking. The time horizon and
perspectives were 30-years and the Veterans Health Administration (VHA). Param-
eter estimates were derived from the literature and analyses of VHA data. First-
and second-orderMonte-Carlo simulationswere conducted 10,000 and 1,000 times,
respectively. RESULTS: The total costs incurred under the assumption of equiva-
lent efficacy ranged from $86,049 for ARA alone to $88,360 for BMD screening alone.
The total QALYs realized ranged from 10.87 for doing nothing to 10.90 for ARA
alone. Compared to the current standard, the incremental cost-effectiveness ratio
(ICER) for BMD screening alone was $34,833/QALY, but ARA alone dominated all
strategies. Resultswere similar but less pronounced for the alternative assumption
of reduced efficacy for treatment in high-risk patients. The third assumption of
non-efficacy in high-risk patients produced an ICER of $154,367/QALY for BMD
screening alone compared to ARA alone, which dominated all other strategies.
CONCLUSIONS: ARA may represent an important tool for minimizing cost and
optimizing fracture prevention outcomes in US veterans.
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